c-MET receptor-targeted fluorescence on the road to image-guided surgery in penile squamous cell carcinoma patients
Vries, H.M. de; Bekers, E.; Oosterom, M.N. van; Karakullukcu, M.B.; Poel, H.G. van der; Leeuwen, F.W.B. van; ...; Brouwer, O.R.

Citation

Version: Publisher's Version
License: Leiden University Non-exclusive license
Downloaded from: https://hdl.handle.net/1887/3567537

Note: To cite this publication please use the final published version (if applicable).
c-MET Receptor–Targeted Fluorescence on the Road to Image-Guided Surgery in Penile Squamous Cell Carcinoma Patients

Hielke M. de Vries¹,², Elise Bekers³, Matthias N. van Oosterom¹,², M. Baris Karakullukçu¹, Henk G. van der Poel¹, Fijs W.B. van Leeuwen¹,², Tessa Buckle¹,²*, and Oscar R. Brouwer¹,²*

¹Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands; ²Interventional Molecular Imaging Laboratory, Department of Radiology, Leiden University Medical Centre, Leiden, The Netherlands; ³Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands; and ⁴Department of Head and Neck Surgery, Netherlands Cancer Institute, Amsterdam, The Netherlands

In penile squamous cell carcinoma (pSCC), primary surgery aims to obtain oncologically safe margins while minimizing mutilation. Surgical guidance provided by receptor-specific tracers could potentially improve margin detection and reduce unnecessary excision of healthy tissue. Here, we present the first results of a prospective feasibility study for real-time intraoperative visualization of pSCC using a fluorescent mesenchymal-epithelial transition factor (c-MET) receptor targeting tracer (EMI-137). Methods: EMI-137 tracer performance was initially assessed ex vivo (n = 10) via incubation of freshly excised pSCC in a solution containing EMI-137 (500 nM). The in vivo potential of c-MET targeting and intraoperative tumor visualization was assessed after intravenous administration of EMI-137 to 5 pSCC patients scheduled for surgical resection using a cyanine-5 fluorescence camera. Fluorescence imaging results were related to standard pathologic tumor evaluation and c-MET immunohistochemistry. Three of the 5 in vivo patients also underwent a sentinel node resection after local administration of the hybrid tracer indocyanine green–99mTc-nanocolloid, which could be imaged using a near-infrared fluorescence camera. Results: No tracer-related adverse events were encountered. Both ex vivo and in vivo, EMI-137 enabled c-MET–based tumor visualization in all patients. Histopathologic analyses showed that all pSCCs expressed c-MET, with expression levels of at least 70% in 14 of 15 patients. Moreover, the highest c-MET expression levels were seen on the outside rim of the tumors, and a visual correlation was found between c-MET expression and fluorescence signal intensity. No complications were encountered when combining primary tumor targeting with lymphatic mapping. As such, simultaneous use of cyanine-5 and indocyanine green in the same patient proved to be feasible. Conclusion: Fluorescence imaging of c-MET receptor–expressing pSCC tumors after intravenous injection of EMI-137 was shown to be feasible and can be combined with fluorescence–based lymphatic mapping. This combination is unique and paves the way toward further development of this surgical guidance approach.

Key Words: penile squamous cell carcinoma; fluorescence-guided surgery; c-MET receptor; receptor-targeted imaging; sentinel node; multicolor

Published online May 14, 2021.
DOI: 10.2967/jnumed.120.261864

Surgical resection remains the mainstay of treatment for primary penile squamous cell carcinoma (pSCC). The potential morbidity of surgery, and the impact on the patient’s sexuality and quality of life, can be minimized by performing penile-sparing surgery in early disease (1). Unfortunately, in today’s practice, positive margins—potentially causing local cancer recurrence—still occur in up to 36% of patients (2). Hence, penile-sparing surgery needs to strike an optimal balance between acquiring oncologically safe resection margins and maximizing residual function and appearance.

Penile cancer surgery is one of the common indications in which image-guided sentinel node resections are applied as routine care (3). The current state of the art relies on lymphatic migration of the near-infrared tracer indocyanine green (ICG)–99mTc-nanocolloid after local administration (Fig. 1) (3).

Expression of the c-MET oncogene has been recorded in up to 87% of pSCC patients (4). Previously, it was shown that use of the far-red (cyanine-5 [Cy5]) fluorescent mesenchymal–epithelial transition factor (c-MET)–targeting peptide EMI-137 (formally known as GE-137), in combination with experimental cameras, was able to facilitate receptor-mediated fluorescence-guided resection of c-MET–positive lesions during colonoscopy (0.13 mg/kg) and esophagoscopy (0.09–0.13 mg/kg) (5–7) after intravenous tracer administration (Fig. 1).

Recent efforts have shown that commercial fluorescence cameras can be modified slightly to allow for Cy5 imaging and can even be used for multicolor imaging applications that allow visualization of 2 complementary tracers in the same patient (8,9).

In this feasibility study in pSCC patients, we evaluated whether ex vivo incubation could predict the in vivo success of c-MET receptor–targeted fluorescence-guided imaging and whether this technology could be applied simultaneously with fluorescence–guided lymphatic mapping (Fig. 1).

MATERIALS AND METHODS

Patients

Fifteen patients with clinical suspicion of pSCC were prospectively included for either ex vivo (n = 10) or in vivo (n = 5) evaluation.
For in vivo use, EMI-137 was prepared for intravenous phosphate-buffered saline to a concentration of 500 nM (20 mL per patient). For ex vivo sample assessment, EMI-137 was dissolved in phosphate-buffered saline to a concentration of 500 nM (20 mL per sample).

On the morning of surgery, the pharmacy department prepared a syringe with the exact EMI-137 dose based on patient weight. Additional details on the fluorescent EMI-137 tracer and an in-depth description of its pharmacokinetics were previously published by Burggraaf et al. (5).

ICG-99mTc-nanocolloid was prepared according to previously described methods (3,10).

**Fluorescence Imaging Modalities**

White-light and far-red fluorescence imaging were conducted using a clinical-grade Cy5 fluorescence camera (Karl Storz Endoskope GmbH; (11)) complemented with in-house-developed image-processing software that allowed color coding of the fluorescence signal for improved visualization and distinction of intensity differences, allowing direct correlation to the tumor-to-background ratio (TBR; the ratio between relative fluorescence units (12) in the tumor and in the surrounding tissue). This image-processing software was built to run in real time and was written in the C++ programming language. To map differences in fluorescence intensity measured to different color values, open-source computer vision libraries (OpenCV) were used. The color map allowed real-time visualization of the fluorescence signal’s distribution within the tissue sample (pseudocolored fluorescence overlay visible on a separate screen) and representation of the TBR via an intensity-based scale bar (fluorescence signal intensity differences represented via a color spectrum). The TBRs were confirmed using ImageJ software by dividing the fluorescent signal intensity in the tumor by the fluorescent signal intensity in background tissue.

Near-infrared fluorescence imaging was performed using a PDE-FIS (FIS-00) fluorescence camera (Hamamatsu Photonics).

**Ex Vivo Assessment of Feasibility of c-MET Targeting**

Resected primary tumor specimens were collected directly after excision and assessed immediately (Fig. 2A). Tumor samples were bisected in the pathology department before ex vivo imaging. For ex vivo assessment of in vivo targeting feasibility, samples were incubated in a solution containing EMI-137 (500 nM, 20 mL) for 5 min. The samples were then rinsed twice with phosphate-buffered saline to clear unbound EMI-137. Samples obtained from patients who received EMI-137 via intravenous administration were imaged without further pretreatment.

**In Vivo Tracer Administration and Fluorescence-Guided Imaging**

Five pSCC patients received intravenous administration of EMI-137 (0.13 mg/kg; (5)) at 3 h (±30 min) before surgery. Adverse events were registered up to 2 wk after intravenous tracer injection. Three patients also underwent a sentinel node resection based on the local intradermal administration of ICG-99mTc-nanocolloid in 3 depots and preoperative nodal identification (lymphoscintigraphy and SPECT/CT imaging at 15 min and 2 h after tracer administration (Fig. 1) (3,10).

To maintain the standard surgical procedure until the ability of EMI-137 to reliably visualize tumor tissue was demonstrated, the operating surgeon was not aware of the intraoperative far-red fluorescence imaging results. The surgical assistant performed Cy5-based imaging. White-light and fluorescence images of the tumor were obtained in the operation room immediately before incision, as well as intra- and postoperatively. Resection of sentinel nodes was based on their anatomic location on SPECT/CT, intraoperative radio guidance (with a γ-probe), and near-infrared fluorescence guidance. Excised samples were also imaged ex vivo.

**Pathologic Assessment**

After ex vivo imaging, samples were formalin-fixed and paraffin-embedded. Three-micrometer sections were subjected to either c-MET or hematoxylin and eosin staining. Immunohistochemistry of the...
<table>
<thead>
<tr>
<th>Parameter</th>
<th>Injection to surgery (min)</th>
<th>cT</th>
<th>cN</th>
<th>cM</th>
<th>Surgery</th>
<th>pT</th>
<th>pN</th>
<th>pGr</th>
<th>PelN</th>
<th>LVI</th>
<th>PNI</th>
<th>R</th>
<th>Diameter (mm)</th>
<th>Infiltration depth (mm)</th>
<th>p16</th>
<th>c-MET expression (%)</th>
<th>c-MET score</th>
<th>TBR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ex vivo</td>
<td>2</td>
<td>1</td>
<td>0</td>
<td></td>
<td>Partial penectomy</td>
<td>3</td>
<td>1</td>
<td>2</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>28</td>
<td>24</td>
<td>Pos</td>
<td>70</td>
<td>0.7</td>
<td>3.2</td>
</tr>
<tr>
<td>Ex vivo</td>
<td>2</td>
<td>0</td>
<td>x</td>
<td></td>
<td>Recircumcision</td>
<td>1a</td>
<td>0</td>
<td>2</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>5</td>
<td>2</td>
<td>Neg</td>
<td>95</td>
<td>0.85</td>
<td>2</td>
</tr>
<tr>
<td>Ex vivo</td>
<td>2</td>
<td>0</td>
<td>x</td>
<td></td>
<td>Partial penectomy</td>
<td>1a</td>
<td>0</td>
<td>1</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>9</td>
<td>2</td>
<td>Neg</td>
<td>90</td>
<td>1.35</td>
<td>2.8</td>
</tr>
<tr>
<td>Ex vivo</td>
<td>2</td>
<td>0</td>
<td>x</td>
<td></td>
<td>Local excision with circumcision</td>
<td>1a</td>
<td>0</td>
<td>2</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>25</td>
<td>3</td>
<td>Neg</td>
<td>90</td>
<td>0.9</td>
<td>2.5</td>
</tr>
<tr>
<td>Ex vivo</td>
<td>2</td>
<td>2</td>
<td>0</td>
<td></td>
<td>Local excision with circumcision</td>
<td>1a</td>
<td>0</td>
<td>2</td>
<td>No</td>
<td>No</td>
<td>—</td>
<td>Yes</td>
<td>48</td>
<td>17</td>
<td>Neg</td>
<td>70</td>
<td>1.5</td>
<td>2.2</td>
</tr>
<tr>
<td>Ex vivo</td>
<td>3</td>
<td>0</td>
<td>x</td>
<td></td>
<td>Subtotal penectomy</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>52</td>
<td>—</td>
<td>Neg</td>
<td>90</td>
<td>0.9</td>
<td>2.6</td>
</tr>
<tr>
<td>Ex vivo</td>
<td>2</td>
<td>0</td>
<td>x</td>
<td></td>
<td>Local excision with circumcision</td>
<td>1a</td>
<td>0</td>
<td>2</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>43</td>
<td>5</td>
<td>Pos</td>
<td>80</td>
<td>1.1</td>
<td>3.4</td>
</tr>
<tr>
<td>Ex vivo</td>
<td>3</td>
<td>3</td>
<td>0</td>
<td></td>
<td>Partial penectomy</td>
<td>3</td>
<td>3</td>
<td>2</td>
<td>No</td>
<td>Yes</td>
<td>—</td>
<td>Yes</td>
<td>33</td>
<td>24</td>
<td>Pos</td>
<td>100</td>
<td>2.3</td>
<td>2.9</td>
</tr>
<tr>
<td>Ex vivo</td>
<td>2</td>
<td>0</td>
<td>x</td>
<td></td>
<td>Partial penectomy</td>
<td>3</td>
<td>0</td>
<td>3</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>21</td>
<td>14</td>
<td>Pos</td>
<td>95</td>
<td>1.65</td>
<td>2.3</td>
</tr>
<tr>
<td>Ex vivo</td>
<td>2</td>
<td>0</td>
<td>x</td>
<td></td>
<td>Partial penectomy</td>
<td>2</td>
<td>0</td>
<td>2</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>55</td>
<td>—</td>
<td>Neg</td>
<td>95</td>
<td>1.2</td>
<td>2.7</td>
</tr>
<tr>
<td>In vivo</td>
<td>263</td>
<td>1</td>
<td>0</td>
<td>x</td>
<td>Local excision</td>
<td>1a</td>
<td>0</td>
<td>2</td>
<td>Yes</td>
<td>No</td>
<td>—</td>
<td>Yes</td>
<td>18</td>
<td>0.5</td>
<td>—</td>
<td>80</td>
<td>1.1</td>
<td>2.1</td>
</tr>
<tr>
<td>In vivo</td>
<td>236</td>
<td>2</td>
<td>3</td>
<td>1</td>
<td>Partial penectomy</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>21</td>
<td>—</td>
<td>Pos</td>
<td>100</td>
<td>1.75</td>
<td>4.2</td>
</tr>
<tr>
<td>In vivo</td>
<td>245</td>
<td>2</td>
<td>0</td>
<td>x</td>
<td>Local excision and circumcision</td>
<td>1a</td>
<td>0</td>
<td>2</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>18</td>
<td>4.5</td>
<td>Neg</td>
<td>30</td>
<td>0.4</td>
<td>2.1</td>
</tr>
<tr>
<td>In vivo</td>
<td>202</td>
<td>2</td>
<td>0</td>
<td>x</td>
<td>Local excision and circumcision</td>
<td>1a</td>
<td>0</td>
<td>2</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>12</td>
<td>2</td>
<td>Pos</td>
<td>100</td>
<td>2.3</td>
<td>2</td>
</tr>
<tr>
<td>In vivo</td>
<td>183</td>
<td>1</td>
<td>0</td>
<td>x</td>
<td>Partial glansectomy</td>
<td>1a</td>
<td>0</td>
<td>2</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>13</td>
<td>6</td>
<td>Neg</td>
<td>90</td>
<td>1.55</td>
<td>3.3</td>
</tr>
</tbody>
</table>

pGr = pathologic differentiation grade; PelN = penile intraepithelial neoplasia; LVI = lymphovascular invasion; PNI = perineural invasion; R = radicality; pos = positive; neg = negative; x = not staged; — = not reported.
formalin-fixed, paraffin-embedded tumor samples was performed on a BenchMark Ultra autostainer (Ventana Medical Systems). Briefly, paraffin sections 3 μm thick were cut, heated at 75°C for 28 min, and deparaffinized in the instrument with EZ Prep solution (Ventana Medical Systems). Heat-induced antigen retrieval was performed using Cell Conditioning 1 (Ventana Medical Systems) for 64 min at 95°C. c-MET was detected using clone SP44 (ready to use, 16 min at 360°C; Roche Diagnostics). Bound c-MET was detected using the UltraView Universal 3,3-diaminobenzidine detection kit (Ventana Medical Systems). Slides were counterstained with hematoxylin and bluing reagent (Ventana Medical Systems).

A dedicated urologic cancer pathologist scored stained sections. Percentages of positive cells were scored for 4 staining intensity categories (−, +, ++, and +++). From this, a c-MET score was calculated by multiplying the percentage of positive tumor area by the intensity of the staining (1 [+] × % positive + 2 [++] × % positive + 3 [+++] × % positive) (13). In short, a c-MET score is the average expression intensity of the complete tumor area. The possible c-MET scores range from 0 (no expression at all) to 3 (100%+++ expression) (13).

Excised lymph nodes were pathologically examined for the presence of macro- or micrometastases or isolated tumor cells, according to previously described protocols (3). The resected penectomy specimens were examined and classified for pathologic tumor stage and grade (14).

**Statistical Analysis**

For continuous variables, the range is reported. The Mann-Whitney U test was used to compare TBR between ex vivo and in vivo samples. Spearman correlation was used for comparison of continuous variables. A P value of less than 0.05 was deemed significant.

**RESULTS**

Initial ex vivo assessment of the feasibility of tumor visualization based on c-MET targeting (Fig. 2) resulted in tumor identification in all 10 tumor specimens. TBRs were in the range of 2.0 ± 0.6 to 3.4 ± 0.3 (Table 1). The identification of tumor tissue was improved by the real-time conversion of the fluorescence output to a heat-map-based color coding (Fig. 2B). Immunohistochemistry confirmed c-MET expression in all tumors and showed the highest c-MET expression at the edge of the tumor (Fig. 2B). Membranous c-MET expression was seen in 70%–100% of cells per specimen (median, 90%), providing c-MET scores in the range of 0.7–2.3 (median, 1.2) (13). Standard pathologic processing was not affected by the presence of Cy5 fluorescence in the surgical sample.

Based on the successful targeting of c-MET in ex vivo surgical specimens, EMI-137 was intravenously administered to 5 patients with pSCC (Fig. 3). Far-red fluorescence imaging allowed identification of the primary tumor (Fig. 3B). Again, color coding obtained after (real-time) image processing provided increased discrimination between the tumor and the surrounding healthy tissue. No interference of renally cleared EMI-137 was observed (Fig. 3B). TBRs after intravenous tracer administration were
similar to those reported for the ex vivo incubation, namely between 2.0 ± 0.4 and 4.2 ± 0.9 (Table 1; P = 0.68).

In the 3 patients who also underwent sentinel node biopsy, preoperatively identified sentinel nodes (Figs. 4A–4C) were removed using a combination of radio guidance and fluorescence guidance. Fluorescence imaging prior to resection of the sentinel node enabled visualization of both lymphatic drainage from the injection site (Fig. 4D) and superficially located sentinel nodes (Fig. 4D). The signal intensity increased when the incision was placed and overlying tissue was resected. All 11 resected sentinel nodes were tumor-negative at pathology. This was underlined by the presence of a clear ICG-related signal in the sentinel node, whereas no clear tumor-related Cy5 signal could be detected (Fig. 4E). Moreover, whereas the injection site for ICG fluorescence-guided surgery avenues (57) could be identified near-infrared fluorescence-guided surgery followed by white-light imaging (58) of ICG–99mTc-nanocolloid and the location of the tumor were within the same field of view (Fig. 1), a near-infrared fluorescence guidance was shown not to be impaired by the presence of far-red fluorescence, or vice versa (Figs. 3B, 4D, and 4E).

Histopathologically, membranous c-MET expression was seen in all tumors (range, 30%–100%; median, 95%), with expression of at least 70% of cells per excised specimen in 4 of 5 tumors, resulting in c-MET scores in the range of 0.4–2.3 (median, 1.7; Table 1). Comparative to the ex vivo specimens, c-MET expression was present throughout the tumor, but the expression was increased at the tumor edge (Fig. 3C).

A (nonsignificant) trend of rising TBR with an increasing c-MET score was observed (Spearman correlation coefficient, 0.203; P = 0.469). Interestingly, the c-MET score and TBR appeared to be higher in patients with LVI, a T stage of at least 2, cN+, and p16 positivity (Table 1), which may support the hypothesis that patients with a worse tumor stage or human papillomavirus–induced tumors might especially benefit from c-MET–targeted surgery.

**DISCUSSION**

In this pilot study on penile cancer patients, we found that EMI-137, a c-MET–specific fluorescent tracer, enabled receptor-mediated ex vivo and in vivo fluorescence-based visualization of primary pSCC (TBR > 2; Table 1). In line with previous literature, no adverse events were recorded after intravenous administration of EMI-137 (5). Furthermore, Cy5-based far-red imaging proved to be compatible with near-infrared fluorescence imaging (ICG–99mTc-nanocolloid) performed during the same procedure. The finding that all pSCC tumors expressed or overexpressed c-MET by at least 70% with preselection of patients and that the tumor tissue could be stained using EMI-137 suggests that c-MET is a potential target for image guidance for pSCC. By masking the surgeon from the far-red fluorescence imaging result during surgery, the standard surgical procedure remained unaffected, and no decisions that could alter patient treatment were made before the assessment of the feasibility of the c-MET targeting approach. However, this approach also enabled the possibility of intraoperative margin assessment. Nevertheless, postoperative assessment underlined the presence of c-MET expression in all samples and that the c-MET–related fluorescence signal was visible at the edge of all tumors (Figs. 2 and 3), indicating possible future potential in this cancer type. The plurality of fluorescent tracers currently being evaluated in clinical studies for a variety of tumor types (e.g., pancreatic cancer, head and neck cancer, and melanoma) also paves the way for the assessment of other possible imaging targets and targeted tracers for penile cancer (15–21).

Our study confirmed the high c-MET expression rate of 87% in pSCC found by Gunia et al. (4). In all 15 patients, far-red fluorescence could be related to the presence of the c-MET receptor at immunohistochemistry. These results are in line with c-MET–specific fluorescent tracer reports from studies on Barrett esophagus and dysplastic colorectal polyps (5–7). This correlation and high expression pattern make the c-MET receptor potentially a promising target for tumor-specific applications in pSCC. Further investigation in a larger patient cohort will be required to substantiate the correlation between c-MET score and TBR, to investigate the ability to reduce positive surgical margins, and to identify the patient group that will benefit most from c-MET–based fluorescence-guided surgery.

This study also showed that primary tumor imaging of far-red (Cy5) fluorescence (peak excitation wavelength, 640 nm; peak emission wavelength, 680 nm) using a first-in-humans laparoscopic camera from Karl Storz Endoskope could be performed alongside near-infrared (ICG) imaging of ICG–99mTc-nanocolloid (peak excitation wavelength, 800 nm; peak emission wavelength, 820 nm) using a clinical-grade fluorescence camera. Fortunately for the patients, the evaluated lymph nodes in this study did not contain metastases, and no Cy5-related signal could be detected in these nodes. Although the utility of targeted tracers for visualization of micrometastases can be debated (22), tumor-targeted far-red imaging has been shown to allow sentinel node mapping successfully (20). The combined use of 2 different fluorescent entities within the same procedure supports the future exploration of multicolor fluorescence-guided surgery avenues (9) that allow visualization of distinct anatomic features (e.g., tumor and sentinel nodes) alongside each other.

**CONCLUSION**

The results from this pilot study suggest that c-MET is a promising target for fluorescence-guided tumor identification, with the potential to improve margin assessment in pSCC. The c-MET–targeted approach proved to be compatible with lymphatic mapping.
performed on the same patient using multicolor fluorescence guidance based on both far-red (Cy5) and near-infrared (ICG) imaging.

**DISCLOSURE**

This research was financially supported by a Netherlands Organization for Scientific Research TTW-VICI grant (grant TTW 16141). EMI-137 was provided by Edinburgh Molecular Imaging (EMI), Karl Storz Endoskope provided the Cy5 fluorescence camera, and the FIS-00 near-infrared fluorescence camera was made available by Hamamatsu Photonics. No other potential conflict of interest relevant to this article was reported.

**ACKNOWLEDGMENTS**

We thank Alwin Huitema, Erik van Muilekom, Jeroen Visser, Eva Offeringa, Florian van Beurden, Nina Heimburger, Danny van Willigen, Fabian van Hensbergen, Krijn Houwing, and Leon Slot for assistance with the set-up, logistics, conduct, chemistry, and software of this study. We also acknowledge the NKI-AVL Core Facility Molecular Pathology & Biobanking (CFMPB) for lab support.

**KEY POINTS**

**QUESTION:** Is the c-MET specific tracer EMI-137 feasible for intraoperative visualization of pSCC?

**PERTINENT FINDING:** This observational fluorescent tracer study describes findings on ten fresh ex vivo tumor specimens and five patients who were intravenously injected with a c-MET specific fluorescent tracer. All tumors were visible via fluorescence imaging, and all expressed c-MET on immunohistochemistry. Thus, c-MET fluorescent imaging appears to be feasible in pSCC. Moreover, this c-MET targeted approach proved to be compatible with lymphatic mapping performed in the same patient.

**IMPLICATIONS FOR PATIENT CARE:** This study indicates that during future pSCC surgery, fluorescent primary tumour visualization is feasible, even in combination with sentinel node procedures. With targeted tracers like EMI-137 and multicolor imaging capabilities, technical capabilities of providing image guidance toward the primary tumour are now emerging.

**REFERENCES**